An update on PTEN modulators–a patent review

Chandra S. Boosani, Palanikumar Gunasekar, Devendra K. Agrawal

Research output: Contribution to journalReview article

Abstract

Introduction: A multitude of cellular and physiological functions have been attributed to the biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting angiogenesis, promoting apoptosis, preventing cell proliferation, and maintaining cellular homeostasis. Based on whether cell growth is needed to be initiated or to be inhibited, enhancing PTEN expression or seeking to inhibit it was pursued. Areas covered: Here the authors provide recent updates to their previous publication on ‘PTEN modulators: A patent review’, and discuss on new specificities that affirm the therapeutic potential of PTEN in promoting neuro-regeneration, stem cell regeneration, autophagy, bone and cartilage regeneration. Also, targeting PTEN appears to be effective in developing new treatment strategies for Parkinson’s disease, Alzheimer’s disease, macular degeneration, immune disorders, asthma, arthritis, lupus, Crohn’s disease, and several cancer types. Expert opinion: PTEN mainly inhibits the PI3k/Akt pathway. However, the PI3k/Akt pathway can be activated by other signaling proteins. Thus, novel treatment strategies that can regulate PTEN alone, or combinational treatment approaches that can induce PTEN and simultaneously affect downstream mediators in the PI3K/Akt pathway, are needed, which were not investigated in detail. Commercial interests associated with molecules that regulate PTEN are discussed here, along with limitations and new possibilities to improve them.

Original languageEnglish (US)
Pages (from-to)881-889
Number of pages9
JournalExpert Opinion on Therapeutic Patents
Volume29
Issue number11
DOIs
StatePublished - Nov 2 2019

Fingerprint

Phosphoric Monoester Hydrolases
Regeneration
Tensins
Bone Regeneration
Immune System Diseases
Autophagy
Macular Degeneration
Expert Testimony
Phosphatidylinositol 3-Kinases
Crohn Disease
Arthritis
Cartilage
Parkinson Disease
Alzheimer Disease
Homeostasis
Stem Cells
Asthma
Cell Proliferation
Apoptosis
Growth

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

An update on PTEN modulators–a patent review. / Boosani, Chandra S.; Gunasekar, Palanikumar; Agrawal, Devendra K.

In: Expert Opinion on Therapeutic Patents, Vol. 29, No. 11, 02.11.2019, p. 881-889.

Research output: Contribution to journalReview article

Boosani, Chandra S. ; Gunasekar, Palanikumar ; Agrawal, Devendra K. / An update on PTEN modulators–a patent review. In: Expert Opinion on Therapeutic Patents. 2019 ; Vol. 29, No. 11. pp. 881-889.
@article{74542f3b0cbe441aa7895a88e43a791c,
title = "An update on PTEN modulators–a patent review",
abstract = "Introduction: A multitude of cellular and physiological functions have been attributed to the biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting angiogenesis, promoting apoptosis, preventing cell proliferation, and maintaining cellular homeostasis. Based on whether cell growth is needed to be initiated or to be inhibited, enhancing PTEN expression or seeking to inhibit it was pursued. Areas covered: Here the authors provide recent updates to their previous publication on ‘PTEN modulators: A patent review’, and discuss on new specificities that affirm the therapeutic potential of PTEN in promoting neuro-regeneration, stem cell regeneration, autophagy, bone and cartilage regeneration. Also, targeting PTEN appears to be effective in developing new treatment strategies for Parkinson’s disease, Alzheimer’s disease, macular degeneration, immune disorders, asthma, arthritis, lupus, Crohn’s disease, and several cancer types. Expert opinion: PTEN mainly inhibits the PI3k/Akt pathway. However, the PI3k/Akt pathway can be activated by other signaling proteins. Thus, novel treatment strategies that can regulate PTEN alone, or combinational treatment approaches that can induce PTEN and simultaneously affect downstream mediators in the PI3K/Akt pathway, are needed, which were not investigated in detail. Commercial interests associated with molecules that regulate PTEN are discussed here, along with limitations and new possibilities to improve them.",
author = "Boosani, {Chandra S.} and Palanikumar Gunasekar and Agrawal, {Devendra K.}",
year = "2019",
month = "11",
day = "2",
doi = "10.1080/13543776.2019.1669562",
language = "English (US)",
volume = "29",
pages = "881--889",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - An update on PTEN modulators–a patent review

AU - Boosani, Chandra S.

AU - Gunasekar, Palanikumar

AU - Agrawal, Devendra K.

PY - 2019/11/2

Y1 - 2019/11/2

N2 - Introduction: A multitude of cellular and physiological functions have been attributed to the biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting angiogenesis, promoting apoptosis, preventing cell proliferation, and maintaining cellular homeostasis. Based on whether cell growth is needed to be initiated or to be inhibited, enhancing PTEN expression or seeking to inhibit it was pursued. Areas covered: Here the authors provide recent updates to their previous publication on ‘PTEN modulators: A patent review’, and discuss on new specificities that affirm the therapeutic potential of PTEN in promoting neuro-regeneration, stem cell regeneration, autophagy, bone and cartilage regeneration. Also, targeting PTEN appears to be effective in developing new treatment strategies for Parkinson’s disease, Alzheimer’s disease, macular degeneration, immune disorders, asthma, arthritis, lupus, Crohn’s disease, and several cancer types. Expert opinion: PTEN mainly inhibits the PI3k/Akt pathway. However, the PI3k/Akt pathway can be activated by other signaling proteins. Thus, novel treatment strategies that can regulate PTEN alone, or combinational treatment approaches that can induce PTEN and simultaneously affect downstream mediators in the PI3K/Akt pathway, are needed, which were not investigated in detail. Commercial interests associated with molecules that regulate PTEN are discussed here, along with limitations and new possibilities to improve them.

AB - Introduction: A multitude of cellular and physiological functions have been attributed to the biological activity of PTEN (Phosphatase and tensin homolog) such as inhibiting angiogenesis, promoting apoptosis, preventing cell proliferation, and maintaining cellular homeostasis. Based on whether cell growth is needed to be initiated or to be inhibited, enhancing PTEN expression or seeking to inhibit it was pursued. Areas covered: Here the authors provide recent updates to their previous publication on ‘PTEN modulators: A patent review’, and discuss on new specificities that affirm the therapeutic potential of PTEN in promoting neuro-regeneration, stem cell regeneration, autophagy, bone and cartilage regeneration. Also, targeting PTEN appears to be effective in developing new treatment strategies for Parkinson’s disease, Alzheimer’s disease, macular degeneration, immune disorders, asthma, arthritis, lupus, Crohn’s disease, and several cancer types. Expert opinion: PTEN mainly inhibits the PI3k/Akt pathway. However, the PI3k/Akt pathway can be activated by other signaling proteins. Thus, novel treatment strategies that can regulate PTEN alone, or combinational treatment approaches that can induce PTEN and simultaneously affect downstream mediators in the PI3K/Akt pathway, are needed, which were not investigated in detail. Commercial interests associated with molecules that regulate PTEN are discussed here, along with limitations and new possibilities to improve them.

UR - http://www.scopus.com/inward/record.url?scp=85073814996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073814996&partnerID=8YFLogxK

U2 - 10.1080/13543776.2019.1669562

DO - 10.1080/13543776.2019.1669562

M3 - Review article

C2 - 31530116

AN - SCOPUS:85073814996

VL - 29

SP - 881

EP - 889

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 11

ER -